Local inflammation4-15

  • Mucus hypersecretion
  • Airway remodeling
  • Airway smooth muscle hypertrophy
  • Epithelial barrier dysfunction
  • Parenchymal destruction

Systemic inflammation4-15

  • Eosinophil trafficking
  • B cell class switching
  • Mast cell degranulation

DUPIXENT is a dual inhibitor of IL-4 and IL-13 signaling, sources of both local and systemic inflammation.1,a

aThe mechanism of dupilumab action has not been definitively established.1

COPD, chronic obstructive pulmonary disease.

See which COPD patients may be appropriate for DUPIXENT

Identifying patients

FREQUENTLY ASKED QUESTIONS

Approximately 40% of COPD patients present with elevated eosinophils, a biomarker of type 2 inflammation. DUPIXENT targets both IL-4 and IL-13 signaling, two of the key sources of type 2 inflammation in COPD. The mechanism of dupilumab action has not been definitively established.16-20

DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled COPD and an eosinophilic phenotype.1

Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm.

LEARN MORE ABOUT PATIENTS WHO MAY BE AFFECTED BY TYPE 2 INFLAMMATION

DUPIXENT is the only dual inhibitor of IL-4 and IL-13 signaling. It is the only FDA-approved biologic indicated for COPD patients. The mechanism of dupilumab action has not been definitively established.1